Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

REGN vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: REGN 5 – 1 MRNA Matrix Metrics: REGN 10 – 0 MRNA

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs MRNA
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
TTM Revenue $16.9B
Forward P/E 14.8x
Beta / 30D Vol 0.30β · 55% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 57
RSI-14: 57.2 · SMA20: $912.90 · SMA50: $829.76
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (REGN 5 – 1 MRNA)

Columns: Metric · REGN · MRNA
1. Valuation Multiples REGN
Forward P/E 14.8x 23.0x
Trailing P/E 20.4x 23.0x
PEG Ratio 1.15x N/M
EV / Revenue 5.6x 33.1x
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% +29.2%
Earnings Growth (YoY) +35.5% -85.1%
TTM Revenue (USD) $16.9B $2.52B
Market Cap $95.5B $80.7B
3. Profitability & Quality REGN
Gross Margin 46.7% -42.0%
Operating Margin 30.4% -80.8%
Net Profit Margin 28.5% -110.5%
Return on Equity (ROE) 14.9% -34.5%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $3.63B -$2.04B
Cash Flow Margin 21.5% -81.0%
Net Cash / Leverage $952M Net Cash $3.03B Net Debt (0.62x D/E)
Dividend Yield 0.39% None (0.00%)
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 39.4% (6th %ile) 89.6% (52nd %ile)
Put/Call OI Skew 0.58x (Call-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 16.3% of Rev ($2.75B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (10) vs MRNA (0)
Institutional Metric REGN MRNA Criterion Row Edge
Market Capitalization
Scale
$95.5B $80.7B Larger Scale REGN
Trailing P/E Ratio
Valuation
20.4x 23.0x Lower Multiple REGN
Forward P/E Ratio
Valuation
14.8x 23.0x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+36.3% +29.2% Higher Growth REGN
Operating Margin (TTM)
Profitability
30.4% -80.8% Higher Margin REGN
Net Profit Margin
Profitability
28.5% -110.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
14.9% -34.5% Higher ROE REGN
52-Week Range Position
Momentum
82% ($592–$992) 67% ($22–$281) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.30β · 55% Vol 2.23β · 78% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite REGN
Trailing 12M Revenue (USD)
Operating Scale
$16.9B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.6x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +16.17 pp
REGN: +12.4% · MRNA: -3.77%
3M Horizon MRNA +29.27 pp
REGN: +11.13% · MRNA: +40.4%
6M Horizon MRNA +271.85 pp
REGN: +44.11% · MRNA: +315.96%
1Y Horizon MRNA +675.44 pp
REGN: +31.01% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period REGN Revenue MRNA Revenue REGN Op. Margin MRNA Op. Margin Margin Leader
FY2018 $5.15B $140M 49.3% -306.0% REGN
FY2019 $6.56B $60M 33.7% -906.8% REGN
FY2020 $8.50B $800M 42.1% -95.0% REGN
FY2021 $16.1B $18.5B 55.7% 72.0% MRNA
FY2022 $12.2B $19.3B 38.9% 48.9% MRNA
FY2023 $13.1B $6.85B 30.9% -61.9% REGN
FY2024 $14.2B $3.24B 28.1% -121.9% REGN
FY2025 $14.3B $1.94B 24.9% -158.1% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN CONSOLIDATION
56d in phase · OBV DISTRIBUTION
Current IV 39.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of REGN ($95,240) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $95.5B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ REGN vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Technically, REGN sits in a Markup phase (RSI 57.2, CONSOLIDATION options structure) and MRNA sits in a Neutral phase (RSI 41.5, CONSOLIDATION options structure).

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

REGN screens cheaper on headline valuation multiples. REGN trades at 14.8x Forward P/E, 20.4x Trailing P/E, 1.15x PEG, and 5.6x EV/Revenue (21.5% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 39.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 55% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.